We investigated the effects of apalcillin on blood coagulation and platelet function. The drug was administered to 21 human volunteers in daily intravenous doses of 75, 150, and 225 mg/kg. These doses evoked abnormalities in platelet aggregation similar to those found with piperacillin and mezlocillin and less striking than those produced by carbenicillin and ticarcillin. Plasma coagulation as measured by prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen concentration was not affected. There were consistent and major reductions in plasma antithrombin III activity, particularly at the two higher dose levels. Of 21 patients, 7 (33%) also manifested maculopapular skin rashes which resolved after discontinuation of the drug.Penicillin and its semisynthetic antibiotic derivatives may affect hemostasis by causing a time-and dose-related defect in platelet aggregation (3, 9). The resultant platelet functional abnormality is most easily demonstrated in vitro by reduced aggregation to an ADP stimulus and in vivo by prolongation of the template bleeding time (7). Severity of the hemostatic defect is variable, however, and seems more predictable and profound with carbenicillin and ticarcillin, for example, than with piperacillin, mezlocillin, and ampicillin (2-4, 6, 7, 9). Apalcillin is a new semisynthetic penicillin with an extended antibacterial spectrum. It is structurally related to ampicillin. We administered apalcillin to normal human volunteers to assess its effects on hemostasis.MATERIALS AND METHODS Subjects. A total of 21 normal, healthy human volunteers (15 males, 6 females), ranging in age from 22 to 34 years (mean age, 24 years), entered Medical Center Del Oro Hospital in Houston, Texas, where the study was done. Initial evaluation included a history and physical examination to exclude anyone with evidence of peptic ulcer disease, gastrointestinal bleeding, renal disease, or penicillin allergy. Also performed were complete blood count, blood chemistries, urinalysis, electrocardiogram, and stool examination for occult blood. Each volunteer provided informed consent.Drug administration. Apalcillin (Wyeth Laboratories, Philadelphia, Pa.) was reconstituted to the desired concentration and then diluted in 100 ml of 5% dextrose in water and infused intravenously every 8 h. The volunteers were divided into three groups of seven. The volunteers received apalcillin daily at a dose of 75 (group A), 150 (group B), or 225 (group C) mg/kg for a 7-day period.Coagulation studies. Blood coagulation and platelet function were evaluated upon initiation of the study, and the evaluation was repeated on days 4, 7, and 14 after the start of antibiotic infusion. Platelet count, prothrombin time, activated partial thromboplastin time, thrombin time, and template bleeding time (Simplate; General Diagnostics, Div. Warner-Lambert Co., Morris Plains, N.J.) followed standard methodology (7). Platelet aggregation was measured in a PAP-3 aggregometer (Bio/Data Corp., Horsham, Pa.). Aggregation was induce...